Clinical Trials
10 trialsNCT04549207 2026-04-07
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
Ottawa Hospital Research Institute
Phase 4 Active not recruiting
NCT00128297 2023-03-28
Pamidronate Administration in Breast Cancer Patients With Bone Metastases
Spanish Breast Cancer Research Group
Phase 4 Completed
NCT02721433 2020-12-02
REaCT-BTA
Ottawa Hospital Research Institute
Phase 4 Completed
NCT00004088 2019-07-02
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT00482378 2018-08-14
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
Mayo Clinic
Phase 1/2 Completed
NCT01907880 2017-07-07
ER11-03
Ottawa Hospital Research Institute
Phase 4 Completed
NCT01067989 2015-07-08
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
HaEmek Medical Center, Israel
Phase 2 Terminated
NCT00083382 2015-06-24
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
University of Arkansas
Phase 2 Completed
NCT00083408 2010-07-05
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
University of Arkansas
Phase 2 Completed
NCT00376883 2007-01-04
Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month
Nordic Myeloma Study Group
Phase 3 Completed